PathRisk: Dynamics of Risk Perception and Risk Behavior in Alcohol Use Disorder and Schizophrenia

Sponsor
University of Konstanz (Other)
Overall Status
Recruiting
CT.gov ID
NCT04985786
Collaborator
Centre for Psychiatry Reichenau, Germany (Other)
240
1
7
21.7
11.1

Study Details

Study Description

Brief Summary

The hyper- or hypo-attribution of risks is deeply related to the core pathological mechanisms of mental disorders and at the same time engaging in risky behaviors influences their course and outcomes. The investigators study risk perception, risk behaviors and underlying brain mechanisms in a longitudinal design in three groups of psychiatric patients who participate in a psychological intervention that is aimed to reduce risk behavior and increase risk perception.

Patients with schizophrenia (SZ), alcohol use disorder (AUD) and both disorders (SZ + AUD) are recruited during psychiatric in-patient treatment and participate in a combined face-to-face and mobile intervention that starts before release and ends four weeks after discharge. The standardized 4-session face-to-face group intervention that is based on motivational interviewing (Miller & Rollnick, 2013) and relapse prevention (Marlatt & Donovan, 2005) and addresses the reduction of disorder-specific risk behaviors, i.e. alcohol use for AUD and SZ+AUD and medication non-adherence for SZ. After discharge, a 4-week ecological momentary intervention (EMI) supports participants to maintain abstinence from risk behaviors and to strengthen coping in high-risk situations relying on mental contrasting and implementation intentions (Oettingen & Gollwitzer, 2011). Participants will be assessed in fMRI and behavioral measurements and by self-report pre and post interventional phase, furthermore they participate in an ecological momentary assessment during the post-discharge phase which assesses risk behaviors, high-risk situations and risk perception in real life contexts.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cognitive Behavioral Therapy for reducing risk behaviors
  • Behavioral: Cognitive Behavioral Therapy for increasing non-risk behaviors
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
240 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Pathological Risk: Dynamics of Risk Perception and Risk Behavior in Alcohol Use Disorder and Schizophrenia
Actual Study Start Date :
Jul 10, 2021
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Apr 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: AUD Intervention

Risk behavior specific intervention, targeting alcohol drinking

Behavioral: Cognitive Behavioral Therapy for reducing risk behaviors
Cognitive Behavioral Therapy to reduce risk behaviors and increase risk perception that combines a standardised face-to-face group therapy before discharge from in-patient treatment and a standardised ecological momentary intervention delivered by mobile phones during the four weeks after discharge. For SZ the target risk behavior is medication non-adherence and for AUD and AUD & SZ it is alcohol use.

Active Comparator: AUD Control

Non-risk behavior specific intervention, targeting cognitive exercises

Behavioral: Cognitive Behavioral Therapy for increasing non-risk behaviors
Cognitive Behavioral Therapy to increase non-risk behaviors that combines a standardised face-to-face group therapy before discharge from in-patient treatment and a standardised ecological momentary intervention delivered by mobile phones during the four weeks after discharge. In this control intervention for patient groups the target behavior is cognitive exercises.

Experimental: AUD & SZ Intervention

Risk behavior specific intervention, targeting alcohol drinking

Behavioral: Cognitive Behavioral Therapy for reducing risk behaviors
Cognitive Behavioral Therapy to reduce risk behaviors and increase risk perception that combines a standardised face-to-face group therapy before discharge from in-patient treatment and a standardised ecological momentary intervention delivered by mobile phones during the four weeks after discharge. For SZ the target risk behavior is medication non-adherence and for AUD and AUD & SZ it is alcohol use.

Active Comparator: AUD & SZ Control

Non-risk behavior specific intervention, targeting cognitive exercises

Behavioral: Cognitive Behavioral Therapy for increasing non-risk behaviors
Cognitive Behavioral Therapy to increase non-risk behaviors that combines a standardised face-to-face group therapy before discharge from in-patient treatment and a standardised ecological momentary intervention delivered by mobile phones during the four weeks after discharge. In this control intervention for patient groups the target behavior is cognitive exercises.

Experimental: SZ Intervention

Risk behavior specific intervention, targeting medication non-adherence

Behavioral: Cognitive Behavioral Therapy for reducing risk behaviors
Cognitive Behavioral Therapy to reduce risk behaviors and increase risk perception that combines a standardised face-to-face group therapy before discharge from in-patient treatment and a standardised ecological momentary intervention delivered by mobile phones during the four weeks after discharge. For SZ the target risk behavior is medication non-adherence and for AUD and AUD & SZ it is alcohol use.

Active Comparator: SZ Control

Non-risk behavior specific intervention, targeting cognitive exercises

Behavioral: Cognitive Behavioral Therapy for increasing non-risk behaviors
Cognitive Behavioral Therapy to increase non-risk behaviors that combines a standardised face-to-face group therapy before discharge from in-patient treatment and a standardised ecological momentary intervention delivered by mobile phones during the four weeks after discharge. In this control intervention for patient groups the target behavior is cognitive exercises.

No Intervention: HC Control

Healthy control subjects will participate in fMRI assessments only

Outcome Measures

Primary Outcome Measures

  1. Change of Nucleus Accumbens activation and connectivity during risky decision making [6 weeks]

    Change of fMRI signal (BOLD) in Balloon Analogue Risk Task

  2. Engagement in risk behaviors [4 weeks]

    Alcohol drinking (for AUD and AUD+SZ) and medication non-adherence (for SZ) as recorded by ecological momentary assessment (EMA)

Secondary Outcome Measures

  1. Risk reappraisal [4 weeks]

    Change of risk perception after critical event depending on the outcome of the critical event (engaging is risk behavior or not) as defined by Klepper et al. (2017)

  2. Activation of amygdala, STS, mPFC and insula during risk evaluation [6 weeks]

    fMRI signal (BOLD) in a trustworthiness task

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • for patient groups: fulfilling the diagnostic criteria for AUD or SZ or both
Exclusion Criteria:

for patient groups and healthy control group:

  • no sufficient command of German language

  • neurological disorder for patient groups:

  • acute psychotic episode

  • acute suicidality or not distanced from self-harming behaviors

  • other substance use disorder (exception: nicotine and caffeine use disorders) for healthy control group:

  • absence of any psychiatric diagnosis (exception: nicotine and caffeine use disorders)

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Konstanz, Research Ward Konstanz Germany 78464

Sponsors and Collaborators

  • University of Konstanz
  • Centre for Psychiatry Reichenau, Germany

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Michael Odenwald, Chief Psychologist Research Ward, University of Konstanz
ClinicalTrials.gov Identifier:
NCT04985786
Other Study ID Numbers:
  • OD 113/3-1
First Posted:
Aug 2, 2021
Last Update Posted:
Aug 11, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 11, 2021